Stock SXTP 60 DEGREES PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus 60 Degrees Pharmaceuticals, Inc.

Equities

SXTP

US83006G1040

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
0.292 USD +0.76% Intraday chart for 60 Degrees Pharmaceuticals, Inc. -7.27% -71.37%
May. 30 60 Degrees Pharmaceuticals, Inc. Enters into an Agreement with Tufts Medical Center in Boston to Conduct the First Clinical Trial of Tafenoquine in Treating Human Babesiosis Patients CI
May. 20 60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study CI

Evolution of the average Target Price on 60 Degrees Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

1c132bb047428208760ce0169d.eTzS-zH0gAYYnHSjI_uM-keqCZIXJjUfRlPFqrKPA1g.T36fi3-X0TVI5ECaFarrnxXEOepgdH5TCiSs5_O5Mi0dXoHOAZjHRy3VNQ~540734c542cfb9e0cd9a5f26b7109465

Analyst Recommendations on 60 Degrees Pharmaceuticals, Inc.

Ascendiant Capital Starts 60 Degrees Pharmaceuticals at Buy With $2.40 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.292 USD
Average target price
1.3 USD
Spread / Average Target
+345.21%
High Price Target
1.3 USD
Spread / Highest target
+345.21%
Low Price Target
1.3 USD
Spread / Lowest Target
+345.21%

Consensus detail

Consensus revision (last 18 months)

Analysts covering 60 Degrees Pharmaceuticals, Inc.

Ascendiant Capital

Ratings for 60 Degrees Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. SXTP Stock
  4. Consensus 60 Degrees Pharmaceuticals, Inc.